Novavax stock plunges after quarterly earnings, but company sees hope in licensing deals
The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...
Novavax Gets FDA Approval To Resume Testing Two Vaccines After Clinical Hold
Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu vaccine that had been put on hold.
Zacks.com on MSN2d
Novavax to Report Q3 Earnings: Here's What to Expect
Novavax NVAX is scheduled to report third-quarter 2024 earnings on Nov. 12, before the opening bell. In the last reported ...
Novavax falls after guidance cut on lower vaccine sales
Novavax (NVAX) stock falls 12% in premarket as company cuts full-year revenue guidance due to a lower sales outlook for its ...
BioPharma Dive2d
FDA lifts pause on Novavax flu vaccine trials
The Food and Drug Administration has cleared Novavax to move forward with testing of a combination vaccine for COVID-19 and ...
How Bad Is This News for Novavax?
However, recent news represents a setback for Novavax's combined vaccine candidate. The U.S. Food and Drug Administration ...
US FDA lifts clinical hold on Novavax's combo COVID-flu shot
The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines, the company said on Monday.
Novavax Q3 Earnings A Week Away - Time To Accept A New Reality
Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...
AOL25d
How Bad Is This News for Novavax?
In early pandemic days, Novavax (NASDAQ: NVAX) shares soared as investors bet on the company's ability to bring a coronavirus vaccine to market. But as the biotech fell behind in the race and ...